{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:19:20Z","timestamp":1792318760816,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jaccao.2022.11.008","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T14:06:09Z","timestamp":1671545169000},"page":"660-669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After\u00a0Immunotherapy"],"prefix":"10.1016","volume":"4","author":[{"given":"Charlotte","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia D.","family":"Drobni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-2086","authenticated-orcid":false,"given":"Carlos A.","family":"Gongora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Zlotoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raza M.","family":"Alvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Taron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula K.","family":"Rambarat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya C.","family":"Mosarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet K.","family":"Raghu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah K.","family":"Gilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Faje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-5832","authenticated-orcid":false,"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mayrhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G.","family":"Neilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jaccao.2022.11.008_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"issue":"12","key":"10.1016\/j.jaccao.2022.11.008_bib2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd4476","article-title":"The immune checkpoint inhibitors: where are we now?","volume":"13","author":"Webster","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.jaccao.2022.11.008_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.jaccao.2022.11.008_bib4","first-page":"35","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity","volume":"3","author":"Zhang","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"issue":"16","key":"10.1016\/j.jaccao.2022.11.008_bib5","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jaccao.2022.11.008_bib6","first-page":"137","article-title":"Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors","volume":"3","author":"Waliany","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"issue":"7","key":"10.1016\/j.jaccao.2022.11.008_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-020-00925-8","article-title":"New insights into mechanisms of immune checkpoint inhibitor-induced cardiovascular toxicity","volume":"22","author":"Khunger","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"13","key":"10.1016\/j.jaccao.2022.11.008_bib8","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week","volume":"74","author":"Ball","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jaccao.2022.11.008_bib9","article-title":"Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease","volume":"8","author":"Lutgens","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"24","key":"10.1016\/j.jaccao.2022.11.008_bib10","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.jaccao.2022.11.008_bib11","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study","volume":"42","author":"D\u2019Souza","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jaccao.2022.11.008_bib12","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jaccao.2022.11.008_bib13","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jaccao.2022.11.008_bib14","doi-asserted-by":"crossref","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","article-title":"Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors","volume":"17","author":"Kennedy","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.jaccao.2022.11.008_bib15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.jaccao.2022.11.008_bib16","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.ATV.0000174800.78362.ec","article-title":"Atherosclerosis in patients with autoimmune disorders","volume":"25","author":"Frosteg\u00e5rd","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.jaccao.2022.11.008_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.autrev.2005.12.006","article-title":"Inflammation: a pivotal link between autoimmune diseases and atherosclerosis","volume":"5","author":"Abou-Raya","year":"2006","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.jaccao.2022.11.008_bib18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.14740\/jocmr2122w","article-title":"The increased cardiovascular risk in patients affected by autoimmune diseases: review of the various manifestations","volume":"7","author":"Durante","year":"2015","journal-title":"J\u00a0Clin Med Res"},{"issue":"1","key":"10.1016\/j.jaccao.2022.11.008_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clim.2015.05.024","article-title":"Cardiovascular disease biomarkers across autoimmune diseases","volume":"161","author":"Ahearn","year":"2015","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.jaccao.2022.11.008_bib20","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaccao.2022.11.008_bib21","article-title":"The efficacy and safety of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease","volume":"11","author":"Tang","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.jaccao.2022.11.008_bib22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00262-019-02321-z","article-title":"Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer","volume":"68","author":"Kehl","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"10.1016\/j.jaccao.2022.11.008_bib23","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"2017 cardiovascular and stroke endpoint definitions for\u00a0clinical trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"issue":"33","key":"10.1016\/j.jaccao.2022.11.008_bib24","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.jaccao.2022.11.008_bib25","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.jaccao.2022.11.008_bib26","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.amjcard.2020.02.016","article-title":"Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors","volume":"125","author":"Oren","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2022.11.008_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"Gong","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jaccao.2022.11.008_bib28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.jaccao.2022.11.008_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11912-020-01002-w","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors: clinical risk factors","volume":"23","author":"Pirozzi","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"10.1016\/j.jaccao.2022.11.008_bib30","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.autrev.2013.03.013","article-title":"Cardiovascular disease in autoimmune rheumatic diseases","volume":"12","author":"Hollan","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.jaccao.2022.11.008_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102925","article-title":"Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus","volume":"21","author":"Restivo","year":"2022","journal-title":"Autoimmunity Rev"},{"issue":"10354","key":"10.1016\/j.jaccao.2022.11.008_bib32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jaccao.2022.11.008_bib33","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Spectrum of cardiovascular toxicities of immune checkpoint inhibitors: a pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jaccao.2022.11.008_bib34","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2022.11.008_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","article-title":"PD-1\/PD-L and autoimmunity: a growing relationship","volume":"310","author":"Zamani","year":"2016","journal-title":"Cell Immunol"},{"issue":"9","key":"10.1016\/j.jaccao.2022.11.008_bib36","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3899\/jrheum.170926","article-title":"Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV\u00a0disease","volume":"45","author":"Jin","year":"2018","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.jaccao.2022.11.008_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40744-019-00189-0","article-title":"Autoimmunity and inflammation link to cardiovascular disease risk in rheumatoid arthritis","volume":"7","author":"DeMizio","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"3","key":"10.1016\/j.jaccao.2022.11.008_bib38","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ijcard.2012.12.085","article-title":"T-cell co-stimulation by CD28\u2013CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development","volume":"168","author":"Ewing","year":"2013","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.jaccao.2022.11.008_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J\u00a0Clin Invest"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322004641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322004641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T19:07:57Z","timestamp":1727377677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087322004641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2666087322004641"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.11.008","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After\u00a0Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}